A Medical Device Daily

Global Med Technologies (Denver), an international e-Health medical information technology company, reported it has completed its previously disclosed acquisition of private European medical software firm Inlog (Lyon, France) and its German operations for a maximum of $11.5 million in a combination of cash, stock and earn-out (Medical Device Daily, April 1, 2008).

The structure of this transaction is expected to be accretive, exclusive of financing costs, in the first full year of operations. Inlog's management is planning to stay with the company.

Inlog, with operations in Lyon and Grenoble, France, and Munich and Alzey, Germany, is a provider of donor center and transfusion information management systems as well as laboratory information systems and other ancillary medical software systems. It currently maintains 700 sites in 15 countries.

As part of the deal, Inlog's shareholders must use $500,000 of the cash proceeds to purchase Global Med common stock in the open market within three months of the closing.

Inlog's unaudited revenues for its fiscal year ended June 30, 2007, were roughly €7 million ($12.4 million), with EBITDA of about €940,000 ($1.45 million).

Global Med Chairman/CEO Michael Ruxin, MD, said, "The acquisition of Inlog by Global Med is a transforming event in the history of our company. As a leading provider of blood and laboratory software applications in 20 countries we are now poised to grow our company in the global marketplace and react quickly to a rapidly changing international market. The accretive nature of the transaction will also further strengthen Global Med's financial position and propel the company to develop more next-generation medical software solutions."

Global Med is a provider of information management software products and services to the healthcare industry.

St. Jude Medical (St. Paul, Minnesota) and EP MedSystems (West Berlin, New Jersey) reported that the deadline for EP MedSystems shareholders to elect the form of consideration they wish to receive in connection with the previously disclosed acquisition of the company by St. Jude Medical will be 5 p.m. EDT on July 1. The transaction is scheduled to close on July 3, provided that the requisite EP shareholder approval is obtained. Final shareholder results will be reported before market opening on July 7.

As previously disclosed, under the terms of the agreement, EP shareholders will receive either $3 in cash or about $3 of St. Jude Medical common stock for each EP share they own for a total of about $92.1 million (MDD, April 10, 2008). EP shareholders have the option to elect between cash and shares, subject to pro-ration such that St. Jude Medical will issue 40% of the total merger consideration in its common stock and 60% in cash

EP MedSystems develops products for use in the cardiac rhythm management or electrophysiology market which are used for visualization, diagnosis and treatment of cardiac rhythm disorders.